Study finds weight loss results drive continued Ozempic use despite nausea and other side effects, based on real world ...

According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. Although rare, semaglutide initiation can lead to ...

Indian pharmaceutical giant Dr Reddy’s Laboratories is gearing up to introduce a generic and significantly cheaper version of Novo Nordisk’s blockbuster weight-loss drug Wegovy. The company’s move ...

Joy Behar revealed on the Feb. 18 episode of The View that she lost 25 pounds using a GLP-1 drug—and she wasn't the only ...

GV Prasad, Co-Chairman & MD, Dr Reddy’s Lab said Canada could offer early market opportunity before competition increases. The company plans launches in multiple markets based on patent and approval ...

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Hims & Hers Health (NYSE:HIMS) launched a compounded semaglutide weight loss pill, then quickly discontinued it after a patent infringement lawsuit from Novo Nordisk. The company is under increased ...

By Tarun Sai Lomte Widely used weight-loss and diabetes drugs show clear benefits, but emerging evidence clarifies their side effects, rare risks, and what clinicians should monitor long term. Review: ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...

Dr Reddy's Laboratories is set to launch a generic version of semaglutide in India on March 21. The company plans to offer both oral and injectable formats at competitive prices. This move aims to ...

Victory Square Technologies Inc. (CSE: VST) (FSE: 6F6) (OTC Pink: VSQTF) (“Victory Square” or the “Company”) provides a ...